Introduction

Pharmaceutical Business Development (BD) rarely consists of a single action. Deciding to in-license an asset requires looking at pipeline gaps and deal intelligence; trying to sell pipeline assets overseas involves packaging value, identifying buyers, and negotiating cross-border terms; when it comes to due diligence and signing, it involves multiple lines including science, IP, commercial, legal, and finance. Performing these tasks scattered across multiple tools and documents can easily lead to inconsistent standards, superficial depth in critical areas, and taking on tasks that fall outside the scope of BD.

The “Pharmaceutical Business BD” introduced below is a community-published Skill that organizes these环节 (links/stages) into a set of callable processes, clarifying which areas require deep BD work, which only provide interfaces, and which are directly externalized.

What is this

“Pharmaceutical Business BD” (Coordinates @user_31815b66/drug-bd, version 1.0.0, category: professional, source: community, publisher: user_31815b66) is used to analyze a drug, therapeutic area, pipeline, or asset from a BD perspective, or to evaluate an external collaboration transaction. It embeds a foundational module, foundation.md, which avoids duplicating clinical basics and calibration rules, and switches depth levels according to the user’s proficiency.

Official URL: https://api.skillhub.cn/user_31815b66/drug-bd
SkillHub Page: https://www.skillhub.cn/skills/user_31815b66/drug-bd

Coverage Capabilities

Divided into eight sections based on business stages, corresponding to the complete chain of a BD transaction from scanning to execution:

  1. BD Strategy & Opportunity Sourcing: Therapeutic area layout, pipeline gaps, opportunity sourcing, deal intelligence.
  2. License-in: In-licensing evaluation, negotiation, signing, post-deal integration.
  3. License-out: Value packaging, buyer identification, cross-border negotiation, covering FDA/EMA regional issues.
  4. M&A & Asset Acquisition: Company acquisition, pipeline/platform asset acquisition.
  5. Co-development / Co-promotion / Strategic Alliance: co-dev / co-promo / JV / strategic cooperation.
  6. Transaction Valuation & Financial Modeling: rNPV, DCF, Comparable Transaction Analysis; deal structure breakdown into Upfront + Milestones + Royalty, including numerical templates.
  7. Due Diligence: Science/Clinical, IP-FTO, Commercial, Legal, Financial; integrated presentation with an interface checklist.
  8. Transaction Architecture, Terms, Negotiation & Execution: Deal design, Term Sheet, negotiation, SPA, post-deal integration management.

Depth Tiers and Responsibility Boundaries

The Skill switches between two tiers based on user proficiency: the “Novice” tier provides detailed explanations plus input checklists, while the “Expert” tier provides concise instructions to directly generate a first draft.

Responsibility boundaries are divided into three categories, which is the main difference between this Skill and general Q&A:

  1. BD Exclusive Functions (Deep Dive): The transaction analysis and execution across the eight modules mentioned above.
  2. Collaborative Interfaces (Interface Only): Science DD → Medical/Commercial DD → Market; IP-FTO → Compliance; Access Value → Market Access; Registration Milestones → Regulatory. These stages are completed by corresponding functions; the Skill is responsible for handover and aligning standards.
  3. Non-BD Boundaries (External): Pure medical evidence generation, pure market access negotiation, pure regulatory filing, pure compliance IP review, pure sales execution.

The built-in foundation.md handles foundational modules to avoid redefining clinical basics and calibration rules.

Installation and Enablement

The Skill is provided in the universal SKILL.md format, sourced from the community, and categorized as professional. Before use, place the Skill in the corresponding location according to the skills directory convention of your Agent, and then call it via trigger phrases.

Verified installation-related fields:

Source: community
Category: professional
requires_api_key: false
pricing_type: alipay
Rating: 100000
Downloads: 1174
Installs: 0

The official materials do not provide differentiated installation commands for Cursor, Codex CLI, or Claude Code, so none are fabricated here; it is recommended to open the official page to confirm the current entry point before actual use.

Typical Usage

The Skill is triggered via natural language, covering common questions from strategy to execution. Example trigger phrases:

"Should we in-license this product?"
"Help me evaluate a license-in deal."
"How do we license-out our pipeline?" / "Find overseas buyers."
"How much is this deal worth / How to calculate rNPV?"
"Is acquiring this company cost-effective?"
"How to collaborate / form an alliance with this company?"
"How to structure the deal?" / "How to negotiate the Term Sheet?"
"What needs to be checked in due diligence?" / "How to manage post-deal integration?"
"How to define BD strategy?" / "Where are the opportunities in this therapeutic area?"
"What recent deals have competitor companies made?"
"How to set up a NewCo?" / "How to split Co-Co?"
"How to write a Teaser / IM?" / "How to write an IC memo?" / "How to write a DD report?"
"How to implement alliance management?" / "How to license-out an in-licensed asset again?"
"What happens to my rights if the upstream partner is acquired?"

When calling, it is recommended to clearly state the background elements (asset/transaction parties, indication, stage, geography, objectives) at once, to facilitate the Skill in outputting at the correct depth tier.

Applicable Scenarios and Notes

Suitable for those who need to make transaction judgments from a BD perspective: evaluating the cost-effectiveness of licensing in or out, structuring deals, writing Term Sheets or IC memos, and organizing due diligence. Stages relying on external real-time data (such as latest deal intelligence, competitor dynamics) should still rely on public information and manual verification; the framework provided by the Skill cannot replace formal due diligence and legal advice.

Three points to note: First, regarding valuation and transaction structure, the assumptions for rNPV, DCF, and comparable transaction methods need to be filled in by the user; second, collaborative interfaces only provide checklists, and deep conclusions must return to the corresponding functions such as medical, IP, and compliance; third, when external collaboration involves cross-border regulations (FDA/EMA), regional rules need to be confirmed separately.

Conclusion

The value of “Pharmaceutical Business BD” lies in breaking down a transaction into executable steps and blocking non-BD tasks outside the boundary, thereby reducing standard discrepancies and overstepping of responsibilities. Official URL: https://api.skillhub.cn/user_31815b66/drug-bd